Fulcrum Therapeutics (FULC) Gains from Investment Securities (2019 - 2025)
Fulcrum Therapeutics (FULC) has 7 years of Gains from Investment Securities data on record, last reported at -$200000.0 in Q4 2025.
- On a quarterly basis, Gains from Investment Securities rose 75.4% to -$200000.0 in Q4 2025 year-over-year; TTM through Mar 2026 was -$913000.0, a 131.61% decrease, with the full-year FY2025 number at $11.6 million, up 24.49% from a year prior.
- Gains from Investment Securities reached -$200000.0 in Q4 2025 per FULC's latest filing, down from $100000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for FULC hit a ceiling of $12.1 million in Q2 2025 and a floor of -$813000.0 in Q4 2024.
- A 5-year average of $2.2 million and a median of $800000.0 in 2024 define the central range for Gains from Investment Securities.
- Peak YoY movement for Gains from Investment Securities: plummeted 89.64% in 2024, then surged 7978.9% in 2025.
- Tracing FULC's Gains from Investment Securities over 5 years: stood at $500000.0 in 2021, then surged by 1085.81% to $5.9 million in 2022, then fell by 2.33% to $5.8 million in 2023, then plummeted by 114.04% to -$813000.0 in 2024, then surged by 75.4% to -$200000.0 in 2025.
- Business Quant data shows Gains from Investment Securities for FULC at -$200000.0 in Q4 2025, $100000.0 in Q3 2025, and $12.1 million in Q2 2025.